All practice questions

4736 questions

All types4,736 Multiple choice2,413 Multiple select567 Numeric127 Matching858 Ordering771

An oncologist evaluates a $52$ -year-old woman during a routine follow-up visit. The patient has HER2-amplified, estrogen receptor-negative early-stage breast cancer. Three months ago, she completed adjuvant therapy with doxorubicin and cyclophosphamide and was subsequently started on maintenance therapy with trastuzumab.

The patient reports feeling well with no shortness of breath, orthopnea, or lower extremity edema. She walks $3$ kilometers daily without difficulty. Vital signs are within normal limits. Physical examination reveals clear lungs bilaterally, no jugular venous distention, and no peripheral edema.

A summary of her echocardiogram reports is provided below:

Parameter	Baseline (Pre-Trastuzumab)	Current (Today)
Left Ventricular Ejection Fraction (LVEF)	$62\%$	$46\%$
Regional Wall Motion	Normal	Diffuse global hypokinesis
Right Ventricular Function	Normal	Normal
Valvular Assessment	Trace mitral regurgitation	Trace mitral regurgitation

Which of the following is the most appropriate next step in managing this patient's therapy?

Hold trastuzumab and repeat echocardiography in 4 weeks

Discontinue trastuzumab permanently and initiate carvedilol

Continue trastuzumab and initiate carvedilol

Admit the patient to the hospital for intravenous furosemide

Obtain cardiac magnetic resonance imaging

Show answer & explanation

Answer: Hold trastuzumab and repeat echocardiography in 4 weeks

Answer

The most appropriate next step is to hold trastuzumab and repeat echocardiography in 4 weeks.

The correct answer involves holding trastuzumab and repeating the echocardiogram in 4 weeks. Trastuzumab is associated with Type II cardiotoxicity, which usually presents as an asymptomatic decline in Left Ventricular Ejection Fraction (LVEF). Standard oncology guidelines mandate holding trastuzumab if the LVEF drops by

\geq 16\%

from baseline, or if the LVEF falls below the institutional limits of normal (usually

< 50\%

) with a

\geq 10\%

absolute drop. This patient's LVEF dropped from

62\%

46\%

, which satisfies both criteria. Because this toxicity is generally reversible and non-dose-dependent, the drug is held temporarily rather than discontinued permanently, and cardiac function is reassessed in 4 weeks to determine if therapy can be safely resumed.

Step-by-Step Solution

Analyze the patient's clinical presentation and echocardiogram results.

The patient is completely asymptomatic, but her LVEF has decreased from

62\%

46\%

(an absolute drop of

16\%

) over three months of trastuzumab therapy.

Identifying the precise magnitude of the LVEF decline is required to accurately apply oncologic monitoring guidelines.

Apply the clinical guidelines for trastuzumab-induced cardiotoxicity.

Because the absolute LVEF decrease is

\geq 16\%

(and the total LVEF is below the normal limit of

50\%

), the drug must be temporarily held to prevent progression to symptomatic heart failure.

Continuing the medication when standard cessation thresholds are met is contraindicated and risks severe patient harm.

Determine the appropriate follow-up monitoring interval.

A repeat echocardiogram should be scheduled in 4 weeks to assess for myocardial recovery.

Because Type II cardiotoxicity is often transient and reversible, reassessment in 4 weeks allows time for recovery while preventing premature permanent discontinuation of a highly effective cancer therapy.

Key Concept

Management of Trastuzumab-Induced Cardiotoxicity

Question 2902Question →

An epidemiology research group is utilizing data and stored biological specimens from a large, ongoing prospective cohort study of $80,000$ healthy adults that began $15$ years ago. The researchers want to investigate whether elevated baseline serum levels of a newly identified inflammatory cytokine, Cytokine-X, are associated with an increased risk of developing multiple sclerosis (MS). During the $15$ -year follow-up period, $120$ participants developed MS. Measuring Cytokine-X is technically demanding and highly expensive; therefore, it is financially impossible to assay the stored baseline serum samples of all $80,000$ participants. The investigators plan to measure the cytokine levels in the baseline serum of the $120$ participants who developed MS and compare them to the baseline serum of a randomly selected subgroup of participants who remained free of the disease, matched for age and sex. Which of the following best describes this study design?

Nested case-control study

Retrospective cohort study

Case-crossover study

Propensity score-matched cohort study

Cross-sectional study

Show answer & explanation

Answer: Nested case-control study

Answer

Nested case-control study

The scenario describes a nested case-control study. In this design, cases of a disease that occur in a defined cohort are identified, and a subset of participants who have not developed the disease are selected as controls. The primary advantage is cost and resource efficiency; it allows investigators to analyze expensive biomarkers (like Cytokine-X) using prospectively collected baseline data without needing to process samples for the entire cohort of

80,000

people. Because the samples were collected at baseline prior to disease onset, recall bias is eliminated and a clear temporal sequence is preserved.

Step-by-Step Solution

Identify the parent population.

The researchers are using participants from an ongoing prospective cohort of

80,000

adults.

Recognizing that the study originates from a well-defined cohort narrows down the methodological possibilities.

Determine how the comparison groups are formed.

Participants are selected based on whether they developed the outcome (the

120

MS cases) or did not (randomly selected controls).

Grouping by outcome status (disease vs. no disease) indicates a case-control approach rather than a cohort approach.

Analyze the timing of exposure measurement.

The exposure (Cytokine-X) is measured from biological specimens collected at baseline, years before the disease developed.

This establishes clear temporality, which combined with the outcome-based sampling within a cohort, confirms the nested case-control design.

Key Concept

A nested case-control study involves identifying cases and a sample of controls from within a predefined prospective cohort to efficiently study expensive or difficult-to-measure baseline exposures.

Question 2903Question →

A clinical research organization is finalizing the methodology for a randomized, placebo-controlled trial evaluating a novel pharmacologic agent for generalized anxiety disorder. The investigators stipulate that they are willing to accept a 5% risk of concluding the agent is effective when it is truly no different from placebo. Furthermore, formal sample size calculations reveal a 0.14 probability of concluding that the drug has no effect when it actually provides a clinically meaningful benefit to patients.

Based on these parameters, what is the planned statistical power of this trial, expressed as a percentage?

Show answer & explanation

Answer: 86

Answer

The planned statistical power of the trial is 86%.

Statistical power is defined mathematically as

1 - \beta

, where

\beta

is the probability of committing a Type II error (failing to detect a true difference). In this scenario, the probability of concluding there is no effect when the drug actually provides a benefit is given as 0.14. Therefore, the statistical power is

1 - 0.14 = 0.86

, which equates to 86%. The 5% risk mentioned in the stem represents the Type I error rate (

\alpha

), which is used to set the significance threshold but is not directly subtracted to calculate power.

Step-by-Step Solution

Identify the Type II error rate (

\beta

) from the scenario.

\beta = 0.14

The scenario defines a 0.14 probability of concluding there is no effect when the drug actually works, which is the definition of a Type II error.

Apply the formula for statistical power.

\text{Power} = 1 - \beta

Power and Type II error are complementary probabilities under the alternative hypothesis.

Calculate the final value.

1 - 0.14 = 0.86

, or

86\%

To find the percentage, the proportion is multiplied by 100.

Key Concept

Statistical power is the probability of correctly rejecting the null hypothesis when the alternative hypothesis is true, calculated as

1 - \beta

(where

\beta

is the Type II error rate).

Estimated Time:1m 0s

Question 2904Question →

A 45-year-old woman returns to the outpatient clinic to review the results of a recent breast biopsy. The pathology report confirms a diagnosis of invasive ductal carcinoma. The physician prepares to deliver this bad news to the patient. Arrange the following physician statements in the most appropriate chronological order according to the established framework for delivering bad news (the SPIKES protocol).

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct order follows the SPIKES protocol: Setting up the interview, assessing the patient's Perception, obtaining an Invitation, giving Knowledge, addressing Emotions, and establishing Strategy and Summary.

The correct order follows the SPIKES protocol for delivering bad news. First, the Setting (S) must be optimized for privacy. Next, the physician assesses the patient's Perception (P) of the situation. Then, an Invitation (I) is obtained to determine how much detail the patient desires. Only after these preparatory steps is Knowledge (K) imparted, giving the diagnosis clearly. Following the news, the physician must address Emotions (E) empathetically. Finally, Strategy and Summary (S) are discussed to formulate a plan moving forward.

Step-by-Step Solution

Identify the clinical objective from the vignette.

The physician must deliver bad news regarding a new cancer diagnosis.

Establishing the clinical goal dictates the most appropriate communication framework to use.

Select the evidence-based communication framework for this scenario.

The SPIKES protocol is the standard, six-step framework for delivering bad news.

SPIKES ensures bad news is delivered empathetically while maximizing comprehension and respecting patient autonomy.

Map the physician's statements to the SPIKES sequence chronologically.

Setting -> Perception -> Invitation -> Knowledge -> Emotions -> Strategy.

Following this exact sequence minimizes psychological trauma, evaluates readiness, and provides clear next steps only after emotions are validated.

Key Concept

The SPIKES protocol for delivering bad news

Estimated Time:1m 0s

Question 2905Question →

A $64$ -year-old man presents to the clinic for a follow-up visit. Over the past four weeks, he has experienced progressive fatigue, an unintentional weight loss of $4$ kg ( $8.8$ lb), and intermittent palpitations. He has a history of ischemic cardiomyopathy with a left ventricular ejection fraction of $30\%$ and recurrent sustained ventricular tachycardia. His medications include lisinopril, carvedilol, spironolactone, and amiodarone. He has been taking amiodarone for the past $2$ years. Vital signs show a blood pressure of $118/76$ mmHg and an irregularly irregular pulse of $112$ /min. Physical examination is notable for a fine resting tremor and warm, diaphoretic skin. The thyroid gland is not enlarged, and there is no tenderness to palpation.

Laboratory studies reveal the following:

Test	Result	Reference Range
Thyroid-stimulating hormone (TSH)	$<0.01$ $\mu$ U/mL	$0.4$ - $4.0$ $\mu$ U/mL
Free T4	$3.5$ ng/dL	$0.7$ - $1.9$ ng/dL
Free T3	$6.2$ pg/mL	$2.0$ - $4.4$ pg/mL

A color flow Doppler ultrasonography of the thyroid gland demonstrates a normal-sized gland with markedly decreased vascular flow.

Which of the following is the most appropriate next step in the pharmacologic management of this patient's thyroid dysfunction?

Initiate oral prednisone

Initiate oral methimazole

Discontinue amiodarone immediately

Administer radioactive iodine ablation

Initiate oral levothyroxine

Show answer & explanation

Answer: Initiate oral prednisone

Answer

The correct answer is to initiate oral prednisone.

The correct answer is to initiate oral prednisone. This patient has developed amiodarone-induced thyrotoxicosis (AIT) during ongoing pharmacologic monitoring. Amiodarone is highly iodine-rich and can cause two distinct types of thyrotoxicosis. AIT type 1 typically occurs in patients with underlying thyroid disease (e.g., multinodular goiter) and is driven by excessive hormone synthesis fueled by the massive iodine load; color flow Doppler ultrasonography demonstrates increased vascularity. In contrast, AIT type 2 occurs in patients with a previously normal thyroid and represents a destructive thyroiditis caused by amiodarone's direct toxic effects on follicular cells. This destruction leads to the release of preformed thyroid hormone, and ultrasound classically demonstrates decreased vascularity. Because AIT type 2 is an inflammatory process rather than a state of true hyperthyroidism, the most appropriate pharmacologic treatment modification is the initiation of glucocorticoids, such as oral prednisone, to reduce inflammation and stabilize the follicular cells.

Step-by-Step Solution

Interpret the clinical presentation and laboratory findings to establish the primary complication of the patient's pharmacotherapy.

The patient has a suppressed TSH with elevated free T4 and T3, alongside symptoms of palpitations, weight loss, and tremor, confirming a diagnosis of thyrotoxicosis secondary to amiodarone.

Accurate interpretation of thyroid function tests is essential before adapting a high-risk medication regimen.

Analyze the color flow Doppler ultrasonography results to distinguish the specific subtype of toxicity.

The ultrasound demonstrates markedly decreased vascular flow, which differentiates amiodarone-induced destructive thyroiditis (type 2) from hyperthyroidism caused by increased hormone synthesis (type 1).

Amiodarone can cause two distinct types of thyrotoxicosis that mandate entirely different treatment modifications.

Select the appropriate pharmacologic management based on the toxicity subtype.

The patient has amiodarone-induced thyrotoxicosis (AIT) type 2. The standard of care is to initiate a glucocorticoid, such as oral prednisone, to suppress the inflammatory destruction of the thyroid follicles.

Unlike AIT type 1, which requires anti-thyroid drugs to block synthesis, AIT type 2 is an inflammatory condition that responds best to glucocorticoids.

Key Concept

Amiodarone-induced thyrotoxicosis type 2 is a destructive thyroiditis characterized by decreased vascularity on ultrasound and requires the initiation of glucocorticoids; it differs from type 1, which involves increased hormone synthesis and is treated with thionamides.

Question 2906Question →

Investigators are planning a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of a novel neuroprotective medication for acute ischemic stroke. The primary outcome is the total volume of cerebral infarction at 90 days. During the design phase, the steering committee modifies the study protocol. Instead of estimating infarct volume using standard non-contrast computed tomography (CT), which has substantial inter-reader variability, the study will now utilize high-resolution magnetic resonance imaging (MRI) with an automated volumetric analysis algorithm. This change significantly improves measurement precision and reduces outcome variance. The anticipated true difference in mean infarct volume between the groups (effect size), the total number of enrolled patients, and the predefined significance level ( $\alpha = 0.05$ ) remain unchanged. Which of the following best describes the expected statistical impact of this protocol modification?

Decreases the probability of making a Type II error and increases statistical power

Decreases the probability of making a Type I error and increases statistical power

Increases the probability of making a Type II error and decreases statistical power

Decreases statistical power but eliminates the risk of confounding bias

Has no impact on statistical power but improves the external validity of the study results

Show answer & explanation

Answer: Decreases the probability of making a Type II error and increases statistical power

Answer

Decreases the probability of making a Type II error and increases statistical power

The correct answer accurately links a reduction in measurement variance to a decrease in Type II error and an increase in statistical power. Statistical power is the probability of correctly rejecting a false null hypothesis (

1 - \beta

). It is dependent on the sample size, the effect size, the predetermined significance level (

\alpha

), and the variance of the outcome measure. By switching to a more precise imaging modality (MRI with automated analysis), the researchers significantly reduce the inter-reader variability and measurement error. This decreases the overall variance (standard deviation) of the data. When variance decreases, the distribution curves for the null and alternative hypotheses become narrower and overlap less. Consequently, the test statistic becomes larger for any given difference in means, decreasing the likelihood of a Type II error (

\beta

) and increasing statistical power. The Type I error (

\alpha

) is a threshold set by the investigator and remains unaffected by measurement precision.

Step-by-Step Solution

Identify which statistical parameters are altered by the protocol change.

The switch from CT to high-resolution MRI with automated analysis reduces measurement error, which directly decreases the variance (standard deviation) of the outcome measure.

Understanding the physical intervention's effect on statistical variables is required to predict the impact on the study's power.

Determine the impact of decreased variance on Type II error (

\beta

A smaller variance creates narrower normal distribution curves for both the null and alternative hypotheses. This reduces the area of overlap between them, meaning the probability of failing to detect a true difference (Type II error) goes down.

Type II error is directly proportional to outcome variance.

Relate Type II error to statistical power.

Since statistical power is defined as

1 - \beta

, a decrease in Type II error (

\beta

) mathematically guarantees an increase in statistical power.

Power and Type II error are inversely related components of hypothesis testing.

Evaluate the impact on Type I error (

\alpha

The probability of a Type I error remains unchanged at the predefined threshold of 0.05.

Type I error is an arbitrary threshold set by the investigators prior to the study, not a variable that fluctuates with measurement precision.

Key Concept

Statistical power (

1 - \beta

) is inversely proportional to the variance of the outcome measure. Reducing measurement error decreases variance, which lowers the Type II error (

\beta

) and increases power, without affecting the predetermined Type I error (

\alpha

Question 2907Question →

A team of pediatric cardiologists is investigating a potential link between maternal use of a newly approved antiemetic during the first trimester and the development of a rare congenital ventricular septal defect (estimated prevalence of $1$ in $15,000$ live births). To conduct the study efficiently, the investigators use a national birth defect registry to identify $250$ infants diagnosed with this specific anomaly. They also select $1,000$ healthy infants from the same registry, matched to the affected infants by birth year, maternal age category, and geographic region. The researchers then conduct structured telephone interviews with all the mothers to ascertain their history of antiemetic use and other medication exposures during early pregnancy. Which of the following statements regarding this study's methodological design and analysis are correct? (Select all that apply)

Select all that apply

The study's design allows for the direct calculation of the incidence of the septal defect in exposed versus unexposed pregnancies.

The odds ratio is the most appropriate statistical measure of association to report for this investigation.

The matching process employed by the investigators specifically aims to eliminate effect modification by maternal age and geographic region.

This methodological approach is considered highly efficient for investigating clinical outcomes with a very low population prevalence.

The method of exposure ascertainment makes the study's findings particularly vulnerable to recall bias.

Show answer & explanation

Answer: The odds ratio is the most appropriate statistical measure of association to report for this investigation.; This methodological approach is considered highly efficient for investigating clinical outcomes with a very low population prevalence.; The method of exposure ascertainment makes the study's findings particularly vulnerable to recall bias.

Answer

The correct statements recognize this as a case-control study, which utilizes the odds ratio, is highly efficient for studying rare diseases, and is particularly susceptible to recall bias.

The clinical scenario describes a retrospective case-control study, identified by the researchers grouping patients based on their outcome status (presence or absence of the septal defect) and then looking backward to assess past exposure (antiemetic use). This specific design is the standard of care for investigating rare diseases, as a prospective cohort would require tracking hundreds of thousands of pregnancies to yield a meaningful number of cases. Because the ratio of cases to controls is predetermined by the researchers rather than occurring naturally, incidence cannot be calculated; thus, the odds ratio is the mandatory measure of association. Finally, whenever past exposures are determined via patient memory—especially following an adverse outcome—the study becomes highly vulnerable to recall bias.

Step-by-Step Solution

Identify the fundamental study design based on the scenario methodology.

The researchers identified subjects based on the presence (cases) or absence (controls) of the outcome, and then looked backward to determine the exposure. This characterizes a retrospective case-control study.

Understanding the core design dictates which statistical measures and biases are applicable.

Evaluate the strengths and limitations of the identified study design.

Because the outcome is very rare (

1

15,000

), a case-control design is the most efficient choice. However, gathering past exposure data via patient interviews creates a significant vulnerability to recall bias.

Study designs must be matched to the prevalence of the outcome and the feasibility of data collection.

Determine the appropriate statistical calculations and control measures for this design.

Case-control studies cannot calculate incidence; they rely on the odds ratio. Furthermore, the matching procedure described (by age and region) is explicitly used to minimize confounding, not effect modification.

Applying the correct epidemiological terminology and statistical parameters is essential for accurately interpreting clinical research.

Key Concept

Case-Control Study Characteristics

Estimated Time:1m 30s

Question 2908Question →

A physician-scientist at a tertiary care clinic is designing a prospective trial to compare the efficacy of two different basal insulin regimens in patients with poorly controlled type 2 diabetes. The initial statistical analysis plan defines the primary endpoint as the absolute reduction in hemoglobin A1c (HbA1c), measured as a continuous variable. A preliminary sample size calculation indicates that $400$ patients are required to detect a clinically significant mean difference of $0.5\%$ between the groups with $80\%$ power and a two-sided $\alpha$ of $0.05$ .

During a peer-review meeting, a colleague suggests altering the primary endpoint to a dichotomous outcome: the proportion of patients who successfully achieve an HbA1c of $< 7.0\%$ by the end of the observation period.

If this modification is adopted and the total sample size remains fixed at $400$ patients, which of the following is the most likely statistical consequence?

The probability of failing to reject a false null hypothesis will increase.

The required inferential analysis will change to an analysis of variance (ANOVA).

The modification will introduce effect modification, necessitating a stratified analysis.

The positive predictive value of the statistical test will artificially increase.

The interpretation of borderline results will become highly susceptible to anchoring bias.

Show answer & explanation

Answer: The probability of failing to reject a false null hypothesis will increase.

Answer

The probability of failing to reject a false null hypothesis will increase.

The correct answer is that the probability of failing to reject a false null hypothesis will increase. Converting a continuous variable (such as absolute HbA1c reduction) into a dichotomous variable (such as whether HbA1c is

< 7.0\%

) results in a significant loss of information regarding the variance and the specific magnitude of change in each individual patient. This loss of data granularity intrinsically reduces the study's statistical power (

1 - \beta

). Because the total sample size remains fixed at

400

patients and the significance level (

\alpha

) is unchanged, a decrease in power mathematically dictates an increase in

\beta

, which is the Type II error rate. A Type II error is defined precisely as failing to reject a false null hypothesis (i.e., failing to detect a true clinical difference between the two insulin regimens when one actually exists).

Step-by-Step Solution

Analyze the proposed change in the primary endpoint.

The endpoint changes from a continuous variable (absolute reduction in HbA1c) to a dichotomous variable (proportion of patients achieving HbA1c < 7.0%).

To understand how the data structure is being altered.

Determine the impact of dichotomizing a continuous variable on statistical power.

Converting continuous data to dichotomous data causes a loss of variance information and data granularity, which inherently decreases the statistical power of the study.

Continuous variables provide more information per subject than categorical variables, allowing for easier detection of differences between groups.

Relate the decrease in statistical power to statistical errors.

Statistical power is defined mathematically as

1 - \beta

. If power decreases while the sample size and

\alpha

remain constant, then

\beta

(the Type II error rate) must increase.

To link the conceptual change in the study design to the formal definitions of statistical parameters.

Define Type II error to identify the correct answer choice.

A Type II error (

\beta

) is the probability of failing to reject a false null hypothesis (i.e., failing to detect a true clinical difference). Therefore, this probability will increase.

To match the derived statistical consequence with the exact wording of the correct option.

Key Concept

Converting a continuous endpoint to a dichotomous endpoint results in a loss of data granularity, which reduces statistical power and consequently increases the probability of a Type II error (failing to reject a false null hypothesis).

Question 2909Question →

During a grand rounds presentation, a cardiologist discusses the findings of the recent VANGUARD trial, which evaluated the addition of a novel aldosterone synthase inhibitor to standard therapy in patients with resistant hypertension. The primary goal of the study was to assess the reduction in major adverse cardiovascular events (MACE) over 4 years.

The trial included 5,000 participants evenly divided into an intervention arm and a standard-care arm. The following event data were recorded during the follow-up period:

Study Arm	Total Participants	MACE (Efficacy Endpoint)	Severe Hyperkalemia (Adverse Event)
Aldosterone Synthase Inhibitor	2,500	175	100
Standard Care	2,500	300	50

A resident is asked to interpret the clinical impact of these findings for a patient considering the new therapy. Based on the provided data, what are the number needed to treat (NNT) to prevent one MACE and the number needed to harm (NNH) for severe hyperkalemia, respectively?

NNT = 5, NNH = 2

NNT = 14, NNH = 50

NNT = 20, NNH = 25

NNT = 20, NNH = 50

NNT = 25, NNH = 20

Show answer & explanation

Answer: NNT = 20, NNH = 50

Answer

NNT = 20, NNH = 50

To determine the clinical impact of the new therapy, we must calculate the absolute risk reduction (ARR) for the benefit and the absolute risk increase (ARI) for the harm.

For efficacy (MACE):
- The baseline risk in the standard care group is

300 / 2,500 = 0.12

(

12\%

).
- The risk in the intervention group is

175 / 2,500 = 0.07

(

7\%

).
- The ARR is the difference between these risks:

0.12 - 0.07 = 0.05

(

5\%

).
- The NNT is the reciprocal of the ARR:

1 / 0.05 = 20

. This means

20

patients need to be treated with the aldosterone synthase inhibitor to prevent one additional MACE.

For harm (Severe Hyperkalemia):
- The risk in the intervention group is

100 / 2,500 = 0.04

(

4\%

).
- The baseline risk in the standard care group is

50 / 2,500 = 0.02

(

2\%

).
- The ARI is the difference:

0.04 - 0.02 = 0.02

(

2\%

).
- The NNH is the reciprocal of the ARI:

1 / 0.02 = 50

. This means for every

50

patients treated, one additional patient will develop severe hyperkalemia compared to standard care.

Step-by-Step Solution

Calculate the event rates for the efficacy endpoint (MACE) in both groups to find the Absolute Risk Reduction (ARR).

Control Event Rate (CER) =

300 / 2,500 = 0.12

(

12\%

). Experimental Event Rate (EER) =

175 / 2,500 = 0.07

(

7\%

). ARR =

0.12 - 0.07 = 0.05

(

5\%

ARR is the absolute difference in the risk of a negative outcome between the control and intervention groups.

Calculate the Number Needed to Treat (NNT).

\text{NNT} = 1 / \text{ARR} = 1 / 0.05 = 20

NNT represents the number of patients who must receive the intervention to prevent one additional adverse outcome.

Calculate the adverse event rates (severe hyperkalemia) in both groups to find the Absolute Risk Increase (ARI).

Experimental Harm Rate =

100 / 2,500 = 0.04

(

4\%

). Control Harm Rate =

50 / 2,500 = 0.02

(

2\%

). ARI =

0.04 - 0.02 = 0.02

(

2\%

ARI is the absolute difference in the risk of harm between the intervention and control groups.

Calculate the Number Needed to Harm (NNH).

\text{NNH} = 1 / \text{ARI} = 1 / 0.02 = 50

NNH represents the number of patients who must receive the intervention to cause one additional adverse event.

Key Concept

Calculation and interpretation of Absolute Risk Reduction (ARR), Absolute Risk Increase (ARI), Number Needed to Treat (NNT), and Number Needed to Harm (NNH).

Question 2910Question →

A team of hepatologists is evaluating the impact of three distinct dietary regimens—Mediterranean, low-fat, and ketogenic—on liver fibrosis progression in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). A total of 150 patients are randomly assigned in equal proportions to one of the three diets for a period of 6 months. The primary outcome is the change in liver stiffness, measured continuously in kilopascals (kPa) using transient elastography, from baseline to the end of the study period. A preliminary analysis of the data reveals that the changes in liver stiffness measurements across all three groups are highly right-skewed and do not follow a normal distribution. Which of the following statistical tests is most appropriate to determine if there is a significant difference in the change in liver stiffness among the three dietary groups?

Analysis of variance

Chi-square test

Kruskal-Wallis test

Mann-Whitney U test

Spearman rank correlation

Show answer & explanation

Answer: Kruskal-Wallis test

Answer

The Kruskal-Wallis test is the correct choice.

The correct statistical test is the Kruskal-Wallis test. In this clinical scenario, the researchers are comparing an outcome across three independent groups (the three different diets). The dependent variable (change in liver stiffness in kPa) is continuous. However, because the data is highly skewed and does not follow a normal distribution, parametric tests (like ANOVA) cannot be used. The Kruskal-Wallis test is the non-parametric equivalent of the one-way ANOVA and is the most appropriate method to analyze continuous, non-normally distributed data across three or more independent groups.

Step-by-Step Solution

Identify the independent variable.

The independent variable is the dietary regimen, which is categorical and consists of three independent groups (Mediterranean, low-fat, ketogenic).

Determining the number of groups dictates whether a two-sample test (e.g., t-test) or a multi-sample test (e.g., ANOVA) is required.

Identify the dependent variable and its scale of measurement.

The dependent variable is the change in liver stiffness, which is measured continuously in kilopascals (kPa).

The nature of the outcome variable (categorical vs. continuous) narrows down the family of applicable statistical tests.

Assess the distribution of the data.

The data is explicitly described as highly right-skewed and non-normally distributed.

Non-normal distribution of a continuous variable requires the use of non-parametric testing rather than parametric testing.

Select the test that fits continuous, non-normal data across three independent groups.

The Kruskal-Wallis test.

The Kruskal-Wallis test is the non-parametric equivalent of one-way ANOVA, specifically designed for three or more independent groups with non-normal continuous or ordinal data.

Key Concept

Selecting the appropriate statistical test based on variable type, number of groups, and data distribution.

Question 2911Question →

During an outpatient endocrine evaluation, a physician evaluates a patient suffering from new-onset, treatment-resistant hypertension, marked proximal myopathy, and progressive truncal adiposity. The patient exhibits classic cutaneous findings, including facial plethora and broad, violaceous abdominal striae. Recent laboratory work definitively established a diagnosis of endogenous hypercortisolism via two distinct, abnormal screening tests: a markedly elevated late-night salivary cortisol and an unsuppressed morning cortisol following a 1-mg overnight dexamethasone suppression test. To elucidate the underlying etiology of this patient's hypercortisolism, which of the following investigations is the most appropriate next step in the diagnostic sequence?

Measurement of plasma adrenocorticotropic hormone

Magnetic resonance imaging of the pituitary gland

High-dose (8-mg) dexamethasone suppression test

Computed tomography of the adrenal glands

Inferior petrosal sinus sampling

Show answer & explanation

Answer: Measurement of plasma adrenocorticotropic hormone

Answer

Measurement of plasma adrenocorticotropic hormone

Once endogenous hypercortisolism (Cushing syndrome) is confirmed with at least two abnormal first-line tests (such as late-night salivary cortisol, 24-hour urine free cortisol, or 1-mg overnight dexamethasone suppression test), the strict next step in the diagnostic sequence is to measure a plasma adrenocorticotropic hormone (ACTH) level. This crucial biochemical step differentiates ACTH-dependent causes (e.g., pituitary adenoma, ectopic ACTH production) from ACTH-independent causes (e.g., adrenal adenoma or carcinoma). Performing anatomical imaging or further dynamic endocrine testing before this basic biochemical categorization can lead to unnecessary, misdirected, or invasive procedures due to the high prevalence of incidentalomas.

Step-by-Step Solution

Evaluate the current diagnostic status of the patient based on the clinical vignette.

The patient has established endogenous Cushing syndrome based on two concordant, abnormal first-line screening tests (elevated salivary cortisol and abnormal 1-mg overnight dexamethasone suppression test).

Before pursuing etiology, the presence of hypercortisolism must be biochemically confirmed to avoid chasing false positives.

Determine the required diagnostic sequence for identifying the etiology of confirmed hypercortisolism.

The algorithm dictates that biochemical localization must precede anatomical localization.

Incidentalomas (both pituitary and adrenal) are common in the general population. Imaging without biochemical guidance often leads to false attribution of the disease source.

Select the specific biochemical test that categorizes the hypercortisolism.

Plasma adrenocorticotropic hormone (ACTH) measurement is selected.

An ACTH level robustly separates ACTH-dependent causes (normal or elevated ACTH) from ACTH-independent causes (suppressed ACTH), dictating whether pituitary or adrenal imaging is subsequently appropriate.

Key Concept

Diagnostic sequencing for Cushing syndrome etiology

Estimated Time:1m 15s

Question 2912Question →

A 71-year-old male resident of a skilled nursing facility is transferred to the acute care hospital due to a 3-day history of progressive confusion and reduced oral intake. His past medical history includes type 2 diabetes mellitus, hypertension, and osteoarthritis. Current medications include amlodipine, metformin, and acetaminophen.

On arrival, his temperature is 36.8°C (98.2°F), pulse is 102/min, blood pressure is 105/60 mm Hg, and respiratory rate is 16/min. The patient is somnolent but arousable and oriented to person only. Physical examination is notable for dry mucous membranes and decreased skin turgor. Cardiopulmonary and abdominal examinations are unremarkable.

Laboratory evaluation reveals:
Serum sodium: 118 mEq/L
Serum potassium: 4.0 mEq/L
Serum chloride: 85 mEq/L
Serum bicarbonate: 25 mEq/L
Blood urea nitrogen (BUN): 38 mg/dL
Serum creatinine: 1.5 mg/dL (baseline: 1.0 mg/dL)
Serum glucose: 140 mg/dL
Serum osmolality: 250 mOsm/kg $H_2O$

Urine studies:
Urine sodium: 12 mEq/L
Urine osmolality: 450 mOsm/kg $H_2O$

The admitting physician initially suspects the syndrome of inappropriate antidiuretic hormone (SIADH) as the primary etiology for the severe hyponatremia. However, upon reviewing the comprehensive clinical and laboratory data, the physician realizes this differential diagnosis is incorrect.

Based on the provided data, which of the following is the most accurate primary differential diagnosis for this patient's hyponatremia?

Hypovolemic hypotonic hyponatremia secondary to dehydration

Euvolemic hypotonic hyponatremia secondary to primary polydipsia

Hypervolemic hypotonic hyponatremia secondary to congestive heart failure

Isotonic hyponatremia (pseudohyponatremia) secondary to hypertriglyceridemia

Hypertonic hyponatremia secondary to uncontrolled hyperglycemia

Show answer & explanation

Answer: Hypovolemic hypotonic hyponatremia secondary to dehydration

Answer

Hypovolemic hypotonic hyponatremia secondary to dehydration

The correct answer identifies that the patient has true hypotonic hyponatremia (serum osmolality 250 mOsm/kg

H_2O

) driven by severe volume depletion. Hypovolemia is evidenced by tachycardia, dry mucous membranes, a BUN-to-creatinine ratio greater than 20:1, and a low urine sodium concentration (less than 20 mEq/L), which demonstrates the kidneys are appropriately trying to conserve sodium and water. SIADH is a euvolemic state typically characterized by a urine sodium

> 40

mEq/L; therefore, the clinical and laboratory signs of profound dehydration make SIADH an incorrect diagnosis.

Step-by-Step Solution

Determine the tonicity of the hyponatremia.

The measured serum osmolality is 250 mOsm/kg

H_2O

(normal: 275-295).

This confirms true hypotonic hyponatremia and rules out isotonic (pseudohyponatremia) and hypertonic (e.g., severe hyperglycemia) causes.

Assess the patient's volume status using clinical and laboratory markers.

The patient exhibits tachycardia, dry mucous membranes, decreased skin turgor, a BUN-to-creatinine ratio

> 20

(38/1.5

\approx

25), and a very low urine sodium (12 mEq/L).

These findings definitively indicate a hypovolemic state with appropriate renal sodium conservation, differentiating it from euvolemic and hypervolemic states.

Formulate the final differential diagnosis based on tonicity and volume status.

The diagnosis is hypovolemic hypotonic hyponatremia, likely secondary to dehydration from poor oral intake.

SIADH causes euvolemic hyponatremia and is typically associated with a urine sodium

> 40

mEq/L. The profound hypovolemia markers completely invalidate SIADH as a diagnostic possibility.

Key Concept

The diagnostic algorithm for hyponatremia involves sequentially assessing serum osmolality to confirm true hypotonicity, followed by an evaluation of clinical volume status and urine sodium to narrow the differential diagnosis and avoid premature closure.

Question 2913Question →

A female patient, aged 64, is evaluated in the ambulatory clinic for ongoing exertional dyspnea. She was diagnosed with heart failure with reduced ejection fraction two years ago following an anterior myocardial infarction. Current symptoms include shortness of breath when walking up a single flight of stairs, consistent with New York Heart Association class II symptoms. Her medical history includes type 2 diabetes mellitus and hypertension.

Current medications are lisinopril, metoprolol succinate, empagliflozin, and torsemide as needed.

Vital signs show a blood pressure of $118/76$ mm Hg and a heart rate of $68$ /min. Physical examination reveals a normal jugular venous pressure, clear lungs, and trace bilateral pedal edema.

Recent laboratory studies:
Sodium: $138$ mEq/L
Potassium: $4.5$ mEq/L
Creatinine: $1.1$ mg/dL (baseline $1.0$ mg/dL)

An echocardiogram from one month ago shows a left ventricular ejection fraction of $32\%$ .

The physician plans to transition the patient from her current angiotensin-converting enzyme inhibitor to sacubitril-valsartan to further reduce the risk of cardiovascular mortality and heart failure hospitalization.

Which of the following is the most appropriate step in implementing this pharmacologic intervention?

Discontinue lisinopril and initiate sacubitril-valsartan after a 36-hour washout period

Maintain lisinopril at the current dose and add sacubitril-valsartan to maximize neurohormonal blockade

Cross-taper the medications by halving the lisinopril dose for three days while starting sacubitril-valsartan

Measure baseline serum B-type natriuretic peptide levels and use them to guide dose titration of the new agent

Order a renal artery duplex ultrasound prior to initiation to rule out bilateral renal artery stenosis

Show answer & explanation

Answer: Discontinue lisinopril and initiate sacubitril-valsartan after a 36-hour washout period

Answer

Discontinue lisinopril and initiate sacubitril-valsartan after a 36-hour washout period.

The correct approach when switching a patient from an angiotensin-converting enzyme (ACE) inhibitor (like lisinopril) to an angiotensin receptor-neprilysin inhibitor (ARNI) (like sacubitril-valsartan) is to enforce a strict 36-hour washout period. Both ACE and neprilysin are enzymes responsible for the degradation of bradykinin. Simultaneous inhibition of both pathways significantly increases bradykinin levels, which can precipitate life-threatening angioedema. The 36-hour window ensures adequate clearance of the ACE inhibitor before neprilysin inhibition begins. Note that this washout period is not required when transitioning from an angiotensin receptor blocker (ARB) to an ARNI.

Step-by-Step Solution

Identify the indication for the pharmacologic change

The patient has symptomatic HFrEF (NYHA class II, LVEF 32%) on optimal medical therapy including an ACE inhibitor, beta-blocker, and SGLT2 inhibitor. Upgrading the ACE inhibitor to an ARNI (sacubitril-valsartan) is guideline-directed.

ARNIs provide superior reduction in morbidity and mortality compared to ACE inhibitors in patients with chronic symptomatic HFrEF.

Determine the specific pharmacokinetic and pharmacodynamic requirements for initiating an ARNI

Sacubitril-valsartan cannot be administered concurrently with an ACE inhibitor due to a synergistic accumulation of bradykinin.

ACE breaks down bradykinin, and neprilysin also breaks down bradykinin. Inhibiting both simultaneously severely increases the risk of angioedema.

Establish the correct protocol for transitioning medications

A minimum 36-hour washout period is required after the last dose of the ACE inhibitor before the first dose of the ARNI can be administered.

This specific timeframe allows for adequate clearance of the ACE inhibitor, mitigating the interaction and safely facilitating the transition.

Key Concept

When transitioning a patient with heart failure from an angiotensin-converting enzyme (ACE) inhibitor to an angiotensin receptor-neprilysin inhibitor (ARNI), a strict 36-hour washout period is required to minimize the risk of angioedema.

Question 2914Question →

A $58$ -year-old man with a history of alcohol-associated cirrhosis is admitted to the intensive care unit with fever, hypotension, and a productive cough. He is diagnosed with severe community-acquired pneumonia and started on broad-spectrum intravenous antibiotics and fluid resuscitation. On the second day of admission, the nurse notes continuous oozing of blood from his peripheral intravenous catheter sites.

Laboratory studies reveal the following:

Laboratory Test	Result	Reference Range
Platelet count	$55,000/mm^3$	$150,000-400,000/mm^3$
Prothrombin time (PT)	$24$ seconds	$11-15$ seconds
Activated partial thromboplastin time (aPTT)	$52$ seconds	$25-40$ seconds
Fibrinogen	$95$ $mg/dL$	$200-400$ $mg/dL$
D-dimer	$4,500$ $ng/mL$	$<500$ $ng/mL$

The attending physician suspects disseminated intravascular coagulation (DIC) secondary to sepsis, but must differentiate this from the patient's baseline coagulopathy of liver disease. Which of the following laboratory findings would most specifically confirm a diagnosis of disseminated intravascular coagulation (DIC) rather than isolated coagulopathy of liver disease in this patient?

Decreased Factor V activity

Decreased Factor VII activity

Prolonged thrombin time

Decreased Factor VIII activity

Decreased antithrombin III activity

Show answer & explanation

Answer: Decreased Factor VIII activity

Answer

Decreased Factor VIII activity

The correct answer is decreased Factor VIII activity. Differentiating the coagulopathy of severe liver disease from disseminated intravascular coagulation (DIC) is a common clinical challenge, as both conditions present with prolonged PT and aPTT, thrombocytopenia, hypofibrinogenemia, and elevated D-dimer levels. However, most coagulation factors are synthesized by the liver, meaning their levels drop in hepatic failure. Factor VIII is a notable exception; it is synthesized primarily by vascular endothelial cells. Consequently, in isolated liver disease, Factor VIII levels are typically normal or even elevated (acting as an acute-phase reactant). Conversely, DIC involves massive systemic activation of the coagulation cascade, which consumes Factor VIII along with other factors. Therefore, a marked decrease in Factor VIII activity specifically confirms the presence of consumptive coagulopathy (DIC) rather than isolated hepatic synthetic dysfunction.

Step-by-Step Solution

Analyze the patient's clinical presentation and initial laboratory abnormalities.

The patient has known severe liver disease (cirrhosis) and presents with sepsis, bleeding, thrombocytopenia, prolonged PT/aPTT, hypofibrinogenemia, and elevated D-dimer.

To establish the differential diagnosis, which in this case centers on overlapping coagulopathies: end-stage liver disease versus sepsis-induced DIC.

Evaluate the overlap in standard laboratory findings between liver disease and DIC.

Both conditions present with prolonged PT and aPTT (impaired synthesis vs. consumption of factors), low platelets (splenic sequestration in portal hypertension vs. consumption in microthrombi), low fibrinogen, and elevated D-dimer/FDPs (reduced hepatic clearance vs. active fibrinolysis).

To recognize that the current lab panel cannot definitively distinguish between the two etiologies.

Identify a specific biomarker that behaves differently in hepatic failure compared to consumptive coagulopathy.

Factor VIII is uniquely synthesized primarily by endothelial cells, unlike most other coagulation factors (e.g., II, V, VII, IX, X) which are synthesized by hepatocytes.

Because Factor VIII is not made in the liver, its production is not impaired by cirrhosis. It is often an acute-phase reactant, so levels are typically normal or elevated in isolated liver disease.

Apply the biomarker to the consumptive state of DIC.

In DIC, widespread activation of the coagulation cascade leads to the severe consumption of all clotting factors, including Factor VIII.

Therefore, observing a significantly decreased Factor VIII activity level in a cirrhotic patient specifically confirms the superimposition of DIC.

Key Concept

Differentiating DIC from the coagulopathy of liver disease using Factor VIII levels

Question 2915Question →

A 42-year-old man presents to the clinic for a routine evaluation. He reports a 2-year history of excessive sweating, fatigue, and loud snoring that frequently wakes his spouse. He mentions that his wedding ring no longer fits and his shoe size has increased from size 10 to 12 over the past few years. He has a history of hypertension and takes amlodipine. Vital signs show a blood pressure of 152/94 mm Hg, pulse of 78/min, and BMI of 31 kg/m². Physical examination reveals coarse facial features, a prominent jaw, and a widened space between his lower incisors. His hands are enlarged and doughy. There is no visual field deficit on confrontation testing. Which of the following is the most appropriate next step in the diagnostic workup of this patient's condition?

Magnetic resonance imaging of the brain

Measurement of a random serum growth hormone level

Measurement of serum insulin-like growth factor 1 level

Oral glucose tolerance test with growth hormone measurement

Polysomnography

Show answer & explanation

Answer: Measurement of serum insulin-like growth factor 1 level

Answer

The most appropriate next step is the measurement of serum insulin-like growth factor 1 (IGF-1) level.

The correct answer is the measurement of serum insulin-like growth factor 1 (IGF-1) level. This patient's presentation of acral enlargement (increasing shoe and ring size), coarse facial features, hyperhidrosis, and secondary complications (hypertension, loud snoring suggesting obstructive sleep apnea) is highly suspicious for acromegaly, a syndrome caused by excess growth hormone (GH) secretion, typically from a pituitary adenoma. Because GH is secreted in a highly pulsatile fashion and has a short half-life, random serum GH levels are not reliable for screening. Instead, the initial test of choice is the measurement of serum IGF-1. IGF-1 is produced by the liver in response to GH, has a longer half-life, and provides a stable, integrated measure of GH secretion over time.

Step-by-Step Solution

Analyze the patient's clinical presentation.

The patient exhibits classic signs of acromegaly, including progressive enlargement of the extremities (increasing shoe size, tight ring), coarse facial features, macrognathia, widened incisor spaces, hyperhidrosis, and secondary complications like hypertension and suspected obstructive sleep apnea.

Recognizing the syndrome is necessary to initiate the specific diagnostic algorithm.

Determine the appropriate initial diagnostic screening test for suspected acromegaly.

Measurement of serum IGF-1 is the initial test of choice.

Growth hormone (GH) is secreted in a highly pulsatile manner by the pituitary gland, making random GH levels uninterpretable. IGF-1 is secreted by the liver in response to GH and has a long half-life, providing a stable reflection of integrated GH secretion.

Sequence the subsequent diagnostic steps if the initial screen is abnormal.

If IGF-1 is elevated, the diagnosis is confirmed with an oral glucose tolerance test (OGTT) with GH measurement. Only after biochemical confirmation should an MRI of the brain (pituitary) be ordered.

Proper test sequencing prevents the pursuit of incidentalomas on imaging and ensures cost-effective, evidence-based care.

Key Concept

The initial diagnostic step for suspected acromegaly is measurement of serum insulin-like growth factor 1 (IGF-1), followed by an oral glucose tolerance test (OGTT) for confirmation, and finally an MRI of the brain to localize the pituitary adenoma.

Estimated Time:1m 0s

Question 2916Question →

While awaiting a routine appointment in the outpatient pulmonary clinic, a $62$ -year-old man suddenly begins coughing up large volumes of bright red blood. Within minutes, he expectorates more than $400\text{ mL}$ of blood into a basin. The patient becomes highly agitated, profoundly diaphoretic, and visibly struggles to breathe. His medical history is significant for pulmonary tuberculosis that was treated $15$ years ago. Clinic staff immediately transfer him to the adjacent emergency department resuscitation bay. Vital signs show a heart rate of $128/\text{min}$ , blood pressure of $115/75\text{ mmHg}$ , and a respiratory rate of $34/\text{min}$ . Pulse oximetry reveals an oxygen saturation of $83\%$ on room air. Chest auscultation demonstrates coarse gurgling and diminished breath sounds predominantly over the right lung fields.

Which of the following is the most appropriate immediate next step in the management of this patient?

Perform endotracheal intubation

Obtain computed tomography angiography of the chest

Transfer the patient for bronchial artery embolization

Perform bedside flexible bronchoscopy

Administer intravenous tranexamic acid

Show answer & explanation

Answer: Perform endotracheal intubation

Answer

Perform endotracheal intubation

The patient is experiencing massive hemoptysis (defined as expectorating >100-600 mL of blood in 24 hours, or any amount causing hemodynamic or respiratory instability). He is presenting with acute respiratory failure, evidenced by profound hypoxemia, severe tachypnea, and respiratory distress. The most common immediate cause of death in massive hemoptysis is asphyxiation from blood flooding the airways, not exsanguination. Therefore, securing the airway via endotracheal intubation is the single most urgent initial stabilization step. Once the airway is protected, the patient should ideally be positioned with the bleeding lung dependent (in this case, right side down, based on auscultation) to prevent blood from spilling into the unaffected lung, followed by definitive diagnosis and treatment (e.g., bronchoscopy or bronchial artery embolization).

Step-by-Step Solution

Recognize the clinical presentation of massive hemoptysis with impending respiratory failure.

The patient has expectorated >400 mL of blood rapidly and is showing severe hypoxemia (SpO2 83%), tachypnea, and respiratory distress.

Identifying the severity of the bleed and its immediate impact on respiratory mechanics dictates the triage priority.

Identify the primary pathophysiological threat to the patient's life in this specific scenario.

The immediate risk is asphyxiation (drowning in blood) due to airway flooding, rather than exsanguination.

The anatomic dead space of the major airways is roughly 150 mL; rapidly coughing up larger volumes easily overwhelms the airway.

Select the intervention that addresses the most immediate life-threatening problem.

Endotracheal intubation is selected as the first step.

Securing the airway guarantees ventilation, provides oxygenation, allows for suctioning, and facilitates subsequent procedures like bronchoscopy.

Key Concept

In the initial stabilization of massive hemoptysis, the primary life-threatening risk is asphyxiation, making airway protection via endotracheal intubation the absolute first priority before diagnostic imaging or source control.

Estimated Time:1m 30s

Question 2917Question →

An elderly man is admitted due to a two-week history of worsening dyspnea, orthopnea, and increasing lower extremity edema. His past medical history is significant for ischemic cardiomyopathy with a left ventricular ejection fraction of $30\%$ . To manage his fluid overload at home, he recently doubled his daily dose of oral torsemide independently.

Upon admission, his blood pressure is $92/58\text{ mmHg}$ , pulse is $108/\text{min}$ , and respiratory rate is $22/\text{min}$ . Jugular venous pressure is visibly elevated. Lung auscultation reveals bilateral basilar crackles, and a third heart sound (S3) is present on cardiac exam.

Laboratory evaluation yields the following results:
Serum chemistry:
Sodium: $132\text{ mEq/L}$
Potassium: $3.1\text{ mEq/L}$
Chloride: $94\text{ mEq/L}$
Bicarbonate: $29\text{ mEq/L}$
Blood urea nitrogen (BUN): $75\text{ mg/dL}$
Creatinine: $2.5\text{ mg/dL}$ (baseline $1.2\text{ mg/dL}$ )

Spot urine chemistry:
Sodium: $66\text{ mEq/L}$
Urea nitrogen: $450\text{ mg/dL}$
Creatinine: $60\text{ mg/dL}$

To evaluate the etiology of the acute kidney injury in the setting of recent loop diuretic use, the medical team decides to calculate a specific fractional excretion index that is less confounded by his medication regimen than sodium excretion.

What is the calculated value of this preferred index, expressed as a percentage?

Show answer & explanation

Answer: 25

Answer

The fractional excretion of urea (FEUrea) is the most accurate index to determine the etiology of acute kidney injury in patients actively receiving diuretic therapy. Diuretics increase distal sodium delivery and urinary sodium excretion, often rendering the FENa

> 1\%

even in severe prerenal states (like heart failure exacerbations). Urea reabsorption occurs primarily in the proximal tubule and is less affected by loop diuretics. The FEUrea is calculated as (Urine Urea Nitrogen

\times

Serum Creatinine) / (BUN

\times

Urine Creatinine)

\times

100. Plugging in the patient's values:

(450 \times 2.5) / (75 \times 60) \times 100 = 25\%

. A value

< 35\%

is strongly indicative of prerenal azotemia, consistent with this patient's cardiorenal syndrome.

Step-by-Step Solution

Identify the clinical problem and the limitation of standard diagnostic indices.

The patient has AKI and is on a loop diuretic, making the Fractional Excretion of Sodium (FENa) unreliable.

Loop diuretics block sodium reabsorption in the loop of Henle, causing natriuresis even when effective arterial blood volume is low, which can falsely elevate the FENa above

1\%

in prerenal states.

Select the appropriate alternative diagnostic index.

The Fractional Excretion of Urea (FEUrea) should be calculated.

Urea handling is linked to proximal tubular fluid reabsorption and is relatively unaffected by loop diuretics, making it a reliable marker for prerenal azotemia in this setting.

Recall the formula for FEUrea.

FE_{Urea} = \left( \frac{U_{Urea} \times P_{Cr}}{BUN \times U_{Cr}} \right) \times 100

This formula normalizes urea clearance to creatinine clearance to determine the fraction of filtered urea that is ultimately excreted.

Substitute the patient's laboratory values into the formula.

Numerator:

450 \times 2.5 = 1125

. Denominator:

75 \times 60 = 4500

. Ratio:

1125 / 4500 = 0.25

. As a percentage:

0.25 \times 100 = 25

Using consistent units (mg/dL) allows the units to cancel out, providing an accurate percentage. A value less than

35\%

confirms prerenal azotemia.

Key Concept

In patients with acute kidney injury who are receiving diuretic therapy, the fractional excretion of urea (FEUrea) is preferred over the fractional excretion of sodium (FENa) to distinguish prerenal azotemia from intrinsic acute tubular necrosis.

Question 2918Question →

A 45-year-old male is evaluated in the infectious disease clinic for a 6-week history of low-grade fevers, drenching night sweats, a productive cough, and a 6.8-kg (15-lb) weight loss. His medical history is significant for severe, seropositive rheumatoid arthritis that has been well-controlled for the past two years. His current medications include methotrexate, infliximab, and as-needed ibuprofen. Social history reveals that he works as a landscaping contractor in Ohio. He returned from a one-week resort vacation in the Dominican Republic two months ago. He has a 10 pack-year history of cigarette smoking but quit 5 years ago. Vital signs show a temperature of 38.2°C (100.8°F), blood pressure of 122/78 mmHg, heart rate of 94/min, and respiratory rate of 18/min. Physical examination reveals bronchial breath sounds and post-tussive crackles in the right upper lung field. A chest radiograph demonstrates a 3.5-cm cavitary lesion in the right upper lobe without significant hilar adenopathy. When evaluating this patient's comprehensive history to establish the primary etiology of his current condition, which of the following elements is the most critical risk factor?

Employment as a landscaping contractor in Ohio

Current treatment with infliximab

Concurrent long-term use of methotrexate

Recent recreational travel to the Dominican Republic

Previous 10 pack-year history of cigarette smoking

Show answer & explanation

Answer: Current treatment with infliximab

Answer

Current treatment with infliximab is the most critical historical risk factor for this patient's likely reactivation tuberculosis.

The correct answer identifies the use of infliximab as the most critical risk factor. Infliximab is a biologic agent that inhibits tumor necrosis factor-alpha (TNF-alpha). TNF-alpha plays an essential, non-redundant role in the formation and maintenance of caseating granulomas that encapsulate and contain Mycobacterium tuberculosis. When patients with latent tuberculosis infection (LTBI) are treated with TNF-alpha inhibitors, the granulomas break down, leading to rapid disease reactivation. The patient's clinical presentation—chronic cough, prominent constitutional symptoms, and an upper lobe cavitary lesion—is the classic manifestation of reactivation tuberculosis. Therefore, among all the details elicited during the medical history, the use of this specific biologic agent is the primary driver of the etiology.

Step-by-Step Solution

Analyze the clinical presentation.

The patient has subacute constitutional symptoms (fevers, night sweats, weight loss) and a right upper lobe cavitary lung lesion.

Identifying the clinical syndrome points strongly toward chronic necrotizing pulmonary infections, classically reactivation tuberculosis (TB).

Evaluate the patient's comprehensive history for risk factors matching the presentation.

The history includes a biologic medication (infliximab), an endemic geographic exposure (Ohio/landscaping), a travel history (Dominican Republic), and a prior smoking history.

Differentiating incidental background findings from the primary disease driver is critical in complex medical histories.

Correlate the specific mechanism of action of the patient's medications with the suspected diagnosis.

Infliximab is a TNF-alpha inhibitor. TNF-alpha is required to maintain the integrity of macrophages and T-cells in the granulomas that sequester latent TB.

Disruption of TNF-alpha leads to granuloma breakdown and explosive reactivation of TB, making this the most potent and direct risk factor for his current condition.

Key Concept

Patients initiating tumor necrosis factor-alpha (TNF-alpha) inhibitors (e.g., infliximab) are at significantly increased risk for the reactivation of latent Mycobacterium tuberculosis due to the destabilization of protective granulomas.

Question 2919Question →

A $48$ -year-old woman is brought to the emergency department due to a $3$ -day history of progressively worsening, severe headache, accompanied by nausea and blurred vision. She has a past medical history of systemic lupus erythematosus and currently takes oral contraceptives. Her blood pressure is $142/88$ mmHg, pulse is $88$ /min, and temperature is $37.1^\circ\text{C}$ ( $98.8^\circ\text{F}$ ). Physical examination reveals bilateral papilledema. Neurologic examination is notable for $4/5$ strength in the left upper and lower extremities. A non-contrast computed tomography (CT) scan of the head is obtained. The images reveal a prominent hyperdense signal within the posterior aspect of the superior sagittal sinus. Additionally, there is a $1.5$ -cm area of hyperdensity in the right frontal parasagittal parenchyma surrounded by a distinct halo of hypodensity. Based on the interpretation of these imaging findings, which of the following is the most appropriate next step in management?

Initiate intravenous heparin therapy

Administer intravenous alteplase

Perform an immediate lumbar puncture

Admit for strict blood pressure control with intravenous nicardipine

Consult neurosurgery for emergent hematoma evacuation

Show answer & explanation

Answer: Initiate intravenous heparin therapy

Answer

The most appropriate next step is to initiate intravenous heparin therapy.

The correct intervention is to initiate intravenous heparin therapy. The patient's presentation of severe headache, papilledema, and focal neurologic deficits in the setting of hypercoagulability (SLE and oral contraceptives) is highly suspicious for cerebral venous sinus thrombosis (CVST). The non-contrast CT confirms this diagnosis by revealing a 'hyperdense sinus' sign, representing the acute clot within the superior sagittal sinus. The associated

1.5

-cm parenchymal hyperdensity is a secondary hemorrhagic venous infarction caused by elevated venous back-pressure and subsequent capillary rupture. A critical, high-yield concept in the management of CVST is that the presence of secondary hemorrhagic transformation is NOT a contraindication to anticoagulation. In fact, therapeutic anticoagulation (using unfractionated heparin or low-molecular-weight heparin) is the standard of care. It prevents further propagation of the thrombus, facilitates venous recanalization, reduces venous pressure, and ultimately prevents further hemorrhage.

Step-by-Step Solution

Analyze the patient's risk factors and clinical presentation.

The patient is a

48

-year-old woman with a hypercoagulable state (systemic lupus erythematosus, oral contraceptive use) presenting with signs of increased intracranial pressure (headache, papilledema) and focal neurologic deficits.

Establishing a high pre-test probability for a thrombotic event helps guide the interpretation of subsequent neuroimaging.

Interpret the specific findings on the non-contrast head CT.

The scan shows a hyperdense signal in the superior sagittal sinus (the 'dense delta sign') and a parasagittal hyperdensity with surrounding hypodensity.

The hyperdense sinus confirms an acute cerebral venous sinus thrombosis (CVST), while the parasagittal lesion represents a secondary venous infarction with hemorrhagic transformation and vasogenic edema.

Determine the therapeutic management based on the imaging interpretation.

Therapeutic anticoagulation (e.g., intravenous heparin or low-molecular-weight heparin) must be initiated.

Anticoagulation halts the propagation of the venous thrombus, restoring venous drainage. Counterintuitively, it is strongly indicated even in the presence of secondary venous hemorrhage, as the hemorrhage is driven by venous back-pressure rather than an primary arterial bleed.

Key Concept

Identifying the 'hyperdense sinus' sign on non-contrast CT allows for the diagnosis of cerebral venous sinus thrombosis (CVST). Even when complicated by secondary hemorrhagic venous infarction, the standard of care remains prompt therapeutic anticoagulation.

Question 2920Question →

Match each laboratory profile of thyroid function to its most likely clinical diagnosis. Reference ranges are as follows: TSH $0.4$ - $4.0$ $\mu$ U/mL; Free T4 $0.9$ - $1.7$ ng/dL; 24-hr Radioactive Iodine Uptake (RAIU) $10\%$ - $30\%$ ; Thyroglobulin $3$ - $40$ ng/mL.

Click a left item, then click its matching right item

Show answer & explanation

Answer

Profile 1 matches Exogenous thyroid hormone ingestion; Profile 2 matches Destructive thyroiditis; Profile 3 matches Graves disease; Profile 4 matches TSH-secreting pituitary adenoma.

The correct matches rely on a step-wise interpretation of thyroid laboratories. First, the relationship between TSH and Free T4 distinguishes primary from secondary (central) causes. Second, RAIU separates de novo synthesis (such as in Graves disease) from destructive or exogenous causes. Finally, serum thyroglobulin precisely differentiates destructive thyroiditis (high thyroglobulin) from exogenous ingestion (low thyroglobulin).

Step-by-Step Solution

Analyze the TSH and Free T4 to determine the primary axis state.

Profiles 1, 2, and 3 show primary thyrotoxicosis (suppressed TSH, high Free T4). Profile 4 shows central hyperthyroidism (inappropriately elevated TSH with high Free T4).

This establishes whether the overproduction source is the thyroid gland itself or the pituitary gland.

Evaluate the Radioactive Iodine Uptake (RAIU) in the profiles showing primary thyrotoxicosis.

Profile 3 has high RAIU, indicating active de novo hormone synthesis. Profiles 1 and 2 have low RAIU, indicating release of preformed hormone or an exogenous source.

RAIU differentiates hyperthyroidism due to active glandular overproduction from thyrotoxicosis without hyperthyroidism.

Use Thyroglobulin levels to differentiate the causes of low-RAIU thyrotoxicosis.

Profile 1 has suppressed thyroglobulin (indicating an exogenous source). Profile 2 has markedly elevated thyroglobulin (indicating destructive thyroiditis).

Thyroglobulin is co-secreted with endogenous thyroid hormone or released during follicular destruction, but its endogenous synthesis is suppressed by exogenous levothyroxine ingestion.

Key Concept

Interpretation of thyroid function tests, Radioactive Iodine Uptake (RAIU), and serum thyroglobulin to determine the specific etiology of thyrotoxicosis.

Estimated Time:1m 30s

PreviousPage 146 / 237Next

All practice questions

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Answer

Step-by-Step Solution

Key Concept